Copyright Reports & Markets. All rights reserved.

Global Endocrine Disrupting Properties Assessment Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Endocrine Disrupting Properties Assessment by Type
    • 1.3.1 Overview: Global Endocrine Disrupting Properties Assessment Market Size by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Global Endocrine Disrupting Properties Assessment Consumption Value Market Share by Type in 2025
    • 1.3.3 In Vitro (Cell-based) Testing
    • 1.3.4 In Vivo (Animal) Testing
    • 1.3.5 In Silico (Computational) Modeling
    • 1.3.6 Others
  • 1.4 Classification of Endocrine Disrupting Properties Assessment by Endocrine Pathway
    • 1.4.1 Overview: Global Endocrine Disrupting Properties Assessment Market Size by Endocrine Pathway: 2021 Versus 2025 Versus 2032
    • 1.4.2 Global Endocrine Disrupting Properties Assessment Consumption Value Market Share by Endocrine Pathway in 2025
    • 1.4.3 Estrogen Pathway Assessment
    • 1.4.4 Androgen Pathway Assessment
    • 1.4.5 Thyroid Pathway Assessment
    • 1.4.6 Steroid Synthesis Pathway Assessment
    • 1.4.7 Others
  • 1.5 Global Endocrine Disrupting Properties Assessment Market by Application
    • 1.5.1 Overview: Global Endocrine Disrupting Properties Assessment Market Size by Application: 2021 Versus 2025 Versus 2032
    • 1.5.2 Environmental Monitoring
    • 1.5.3 Food Safety
    • 1.5.4 Cosmetics and Personal Care Products
    • 1.5.5 Public Health and Disease Prevention
    • 1.5.6 Others
  • 1.6 Global Endocrine Disrupting Properties Assessment Market Size & Forecast
  • 1.7 Global Endocrine Disrupting Properties Assessment Market Size and Forecast by Region
    • 1.7.1 Global Endocrine Disrupting Properties Assessment Market Size by Region: 2021 VS 2025 VS 2032
    • 1.7.2 Global Endocrine Disrupting Properties Assessment Market Size by Region, (2021-2032)
    • 1.7.3 North America Endocrine Disrupting Properties Assessment Market Size and Prospect (2021-2032)
    • 1.7.4 Europe Endocrine Disrupting Properties Assessment Market Size and Prospect (2021-2032)
    • 1.7.5 Asia-Pacific Endocrine Disrupting Properties Assessment Market Size and Prospect (2021-2032)
    • 1.7.6 South America Endocrine Disrupting Properties Assessment Market Size and Prospect (2021-2032)
    • 1.7.7 Middle East & Africa Endocrine Disrupting Properties Assessment Market Size and Prospect (2021-2032)

2 Company Profiles

  • 2.1 Labcorp
    • 2.1.1 Labcorp Details
    • 2.1.2 Labcorp Major Business
    • 2.1.3 Labcorp Endocrine Disrupting Properties Assessment Product and Solutions
    • 2.1.4 Labcorp Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Labcorp Recent Developments and Future Plans
  • 2.2 Eurofins Scientific
    • 2.2.1 Eurofins Scientific Details
    • 2.2.2 Eurofins Scientific Major Business
    • 2.2.3 Eurofins Scientific Endocrine Disrupting Properties Assessment Product and Solutions
    • 2.2.4 Eurofins Scientific Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Eurofins Scientific Recent Developments and Future Plans
  • 2.3 Intertek
    • 2.3.1 Intertek Details
    • 2.3.2 Intertek Major Business
    • 2.3.3 Intertek Endocrine Disrupting Properties Assessment Product and Solutions
    • 2.3.4 Intertek Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Intertek Recent Developments and Future Plans
  • 2.4 Charles River Laboratories
    • 2.4.1 Charles River Laboratories Details
    • 2.4.2 Charles River Laboratories Major Business
    • 2.4.3 Charles River Laboratories Endocrine Disrupting Properties Assessment Product and Solutions
    • 2.4.4 Charles River Laboratories Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Charles River Laboratories Recent Developments and Future Plans
  • 2.5 PerkinElmer
    • 2.5.1 PerkinElmer Details
    • 2.5.2 PerkinElmer Major Business
    • 2.5.3 PerkinElmer Endocrine Disrupting Properties Assessment Product and Solutions
    • 2.5.4 PerkinElmer Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 PerkinElmer Recent Developments and Future Plans
  • 2.6 Smithers
    • 2.6.1 Smithers Details
    • 2.6.2 Smithers Major Business
    • 2.6.3 Smithers Endocrine Disrupting Properties Assessment Product and Solutions
    • 2.6.4 Smithers Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Smithers Recent Developments and Future Plans
  • 2.7 Fera Science
    • 2.7.1 Fera Science Details
    • 2.7.2 Fera Science Major Business
    • 2.7.3 Fera Science Endocrine Disrupting Properties Assessment Product and Solutions
    • 2.7.4 Fera Science Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Fera Science Recent Developments and Future Plans
  • 2.8 Staphyt
    • 2.8.1 Staphyt Details
    • 2.8.2 Staphyt Major Business
    • 2.8.3 Staphyt Endocrine Disrupting Properties Assessment Product and Solutions
    • 2.8.4 Staphyt Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Staphyt Recent Developments and Future Plans
  • 2.9 TransGenic
    • 2.9.1 TransGenic Details
    • 2.9.2 TransGenic Major Business
    • 2.9.3 TransGenic Endocrine Disrupting Properties Assessment Product and Solutions
    • 2.9.4 TransGenic Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 TransGenic Recent Developments and Future Plans
  • 2.10 ToxStrategies
    • 2.10.1 ToxStrategies Details
    • 2.10.2 ToxStrategies Major Business
    • 2.10.3 ToxStrategies Endocrine Disrupting Properties Assessment Product and Solutions
    • 2.10.4 ToxStrategies Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 ToxStrategies Recent Developments and Future Plans
  • 2.11 LAUS
    • 2.11.1 LAUS Details
    • 2.11.2 LAUS Major Business
    • 2.11.3 LAUS Endocrine Disrupting Properties Assessment Product and Solutions
    • 2.11.4 LAUS Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 LAUS Recent Developments and Future Plans
  • 2.12 Creative Bioarray
    • 2.12.1 Creative Bioarray Details
    • 2.12.2 Creative Bioarray Major Business
    • 2.12.3 Creative Bioarray Endocrine Disrupting Properties Assessment Product and Solutions
    • 2.12.4 Creative Bioarray Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 Creative Bioarray Recent Developments and Future Plans
  • 2.13 Creative Proteomics
    • 2.13.1 Creative Proteomics Details
    • 2.13.2 Creative Proteomics Major Business
    • 2.13.3 Creative Proteomics Endocrine Disrupting Properties Assessment Product and Solutions
    • 2.13.4 Creative Proteomics Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 Creative Proteomics Recent Developments and Future Plans
  • 2.14 Compliance Services International
    • 2.14.1 Compliance Services International Details
    • 2.14.2 Compliance Services International Major Business
    • 2.14.3 Compliance Services International Endocrine Disrupting Properties Assessment Product and Solutions
    • 2.14.4 Compliance Services International Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026)
    • 2.14.5 Compliance Services International Recent Developments and Future Plans
  • 2.15 Xenometrix
    • 2.15.1 Xenometrix Details
    • 2.15.2 Xenometrix Major Business
    • 2.15.3 Xenometrix Endocrine Disrupting Properties Assessment Product and Solutions
    • 2.15.4 Xenometrix Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026)
    • 2.15.5 Xenometrix Recent Developments and Future Plans
  • 2.16 Shenyang SYRICI Testing
    • 2.16.1 Shenyang SYRICI Testing Details
    • 2.16.2 Shenyang SYRICI Testing Major Business
    • 2.16.3 Shenyang SYRICI Testing Endocrine Disrupting Properties Assessment Product and Solutions
    • 2.16.4 Shenyang SYRICI Testing Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026)
    • 2.16.5 Shenyang SYRICI Testing Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Endocrine Disrupting Properties Assessment Revenue and Share by Players (2021-2026)
  • 3.2 Market Share Analysis (2025)
    • 3.2.1 Market Share of Endocrine Disrupting Properties Assessment by Company Revenue
    • 3.2.2 Top 3 Endocrine Disrupting Properties Assessment Players Market Share in 2025
    • 3.2.3 Top 6 Endocrine Disrupting Properties Assessment Players Market Share in 2025
  • 3.3 Endocrine Disrupting Properties Assessment Market: Overall Company Footprint Analysis
    • 3.3.1 Endocrine Disrupting Properties Assessment Market: Region Footprint
    • 3.3.2 Endocrine Disrupting Properties Assessment Market: Company Product Type Footprint
    • 3.3.3 Endocrine Disrupting Properties Assessment Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Endocrine Disrupting Properties Assessment Consumption Value and Market Share by Type (2021-2026)
  • 4.2 Global Endocrine Disrupting Properties Assessment Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

  • 5.1 Global Endocrine Disrupting Properties Assessment Consumption Value Market Share by Application (2021-2026)
  • 5.2 Global Endocrine Disrupting Properties Assessment Market Forecast by Application (2027-2032)

6 North America

  • 6.1 North America Endocrine Disrupting Properties Assessment Consumption Value by Type (2021-2032)
  • 6.2 North America Endocrine Disrupting Properties Assessment Market Size by Application (2021-2032)
  • 6.3 North America Endocrine Disrupting Properties Assessment Market Size by Country
    • 6.3.1 North America Endocrine Disrupting Properties Assessment Consumption Value by Country (2021-2032)
    • 6.3.2 United States Endocrine Disrupting Properties Assessment Market Size and Forecast (2021-2032)
    • 6.3.3 Canada Endocrine Disrupting Properties Assessment Market Size and Forecast (2021-2032)
    • 6.3.4 Mexico Endocrine Disrupting Properties Assessment Market Size and Forecast (2021-2032)

7 Europe

  • 7.1 Europe Endocrine Disrupting Properties Assessment Consumption Value by Type (2021-2032)
  • 7.2 Europe Endocrine Disrupting Properties Assessment Consumption Value by Application (2021-2032)
  • 7.3 Europe Endocrine Disrupting Properties Assessment Market Size by Country
    • 7.3.1 Europe Endocrine Disrupting Properties Assessment Consumption Value by Country (2021-2032)
    • 7.3.2 Germany Endocrine Disrupting Properties Assessment Market Size and Forecast (2021-2032)
    • 7.3.3 France Endocrine Disrupting Properties Assessment Market Size and Forecast (2021-2032)
    • 7.3.4 United Kingdom Endocrine Disrupting Properties Assessment Market Size and Forecast (2021-2032)
    • 7.3.5 Russia Endocrine Disrupting Properties Assessment Market Size and Forecast (2021-2032)
    • 7.3.6 Italy Endocrine Disrupting Properties Assessment Market Size and Forecast (2021-2032)

8 Asia-Pacific

  • 8.1 Asia-Pacific Endocrine Disrupting Properties Assessment Consumption Value by Type (2021-2032)
  • 8.2 Asia-Pacific Endocrine Disrupting Properties Assessment Consumption Value by Application (2021-2032)
  • 8.3 Asia-Pacific Endocrine Disrupting Properties Assessment Market Size by Region
    • 8.3.1 Asia-Pacific Endocrine Disrupting Properties Assessment Consumption Value by Region (2021-2032)
    • 8.3.2 China Endocrine Disrupting Properties Assessment Market Size and Forecast (2021-2032)
    • 8.3.3 Japan Endocrine Disrupting Properties Assessment Market Size and Forecast (2021-2032)
    • 8.3.4 South Korea Endocrine Disrupting Properties Assessment Market Size and Forecast (2021-2032)
    • 8.3.5 India Endocrine Disrupting Properties Assessment Market Size and Forecast (2021-2032)
    • 8.3.6 Southeast Asia Endocrine Disrupting Properties Assessment Market Size and Forecast (2021-2032)
    • 8.3.7 Australia Endocrine Disrupting Properties Assessment Market Size and Forecast (2021-2032)

9 South America

  • 9.1 South America Endocrine Disrupting Properties Assessment Consumption Value by Type (2021-2032)
  • 9.2 South America Endocrine Disrupting Properties Assessment Consumption Value by Application (2021-2032)
  • 9.3 South America Endocrine Disrupting Properties Assessment Market Size by Country
    • 9.3.1 South America Endocrine Disrupting Properties Assessment Consumption Value by Country (2021-2032)
    • 9.3.2 Brazil Endocrine Disrupting Properties Assessment Market Size and Forecast (2021-2032)
    • 9.3.3 Argentina Endocrine Disrupting Properties Assessment Market Size and Forecast (2021-2032)

10 Middle East & Africa

  • 10.1 Middle East & Africa Endocrine Disrupting Properties Assessment Consumption Value by Type (2021-2032)
  • 10.2 Middle East & Africa Endocrine Disrupting Properties Assessment Consumption Value by Application (2021-2032)
  • 10.3 Middle East & Africa Endocrine Disrupting Properties Assessment Market Size by Country
    • 10.3.1 Middle East & Africa Endocrine Disrupting Properties Assessment Consumption Value by Country (2021-2032)
    • 10.3.2 Turkey Endocrine Disrupting Properties Assessment Market Size and Forecast (2021-2032)
    • 10.3.3 Saudi Arabia Endocrine Disrupting Properties Assessment Market Size and Forecast (2021-2032)
    • 10.3.4 UAE Endocrine Disrupting Properties Assessment Market Size and Forecast (2021-2032)

11 Market Dynamics

  • 11.1 Endocrine Disrupting Properties Assessment Market Drivers
  • 11.2 Endocrine Disrupting Properties Assessment Market Restraints
  • 11.3 Endocrine Disrupting Properties Assessment Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Endocrine Disrupting Properties Assessment Industry Chain
  • 12.2 Endocrine Disrupting Properties Assessment Upstream Analysis
  • 12.3 Endocrine Disrupting Properties Assessment Midstream Analysis
  • 12.4 Endocrine Disrupting Properties Assessment Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Endocrine Disrupting Properties Assessment market size was valued at US$ 215 million in 2025 and is forecast to a readjusted size of US$ 329 million by 2032 with a CAGR of 6.4% during review period.
    Endocrine Disrupting Properties Assessment refers to the scientific and regulatory evaluation of whether a chemical substance, mixture, ingredient, material or active substance has properties that may interfere with the endocrine system and lead to adverse effects in humans or the environment. The assessment typically integrates existing toxicological data, endocrine activity screening, mechanistic evidence, apical adverse-effect studies, exposure and relevance considerations, and a weight-of-evidence judgement based on recognized regulatory frameworks and test guidelines. In market terms, it covers laboratory testing, data gap analysis, study design, dossier review, expert interpretation and compliance support for chemicals, pesticides, biocides, cosmetics ingredients, industrial materials and other regulated substances. OECD guidance focuses on standardized test guidelines for evaluating chemicals for endocrine disruption, including estrogen, androgen, thyroid and steroidogenesis-related modalities, while EU regulatory frameworks have established scientific criteria for identifying endocrine disruptors in biocidal and plant protection product areas.
    The Endocrine Disrupting Properties Assessment market is becoming an increasingly important segment of chemical safety, regulatory toxicology and compliance testing services. Demand is mainly driven by stricter regulatory attention to chemicals that may interfere with hormonal systems, especially under European chemical, biocidal product and plant protection product frameworks. The market is not limited to a single laboratory test, but combines in vitro screening, in vivo toxicology data, mechanistic interpretation, weight-of-evidence evaluation, regulatory dossier preparation and expert review. Service providers with strong experience in OECD test guidelines, ECHA and EFSA guidance, REACH, CLP, biocides, pesticides and cosmetics-related compliance are likely to gain advantages, because customers need not only test results, but also defensible scientific conclusions that can support product registration, substance approval, risk assessment and market access. OECD describes its work as supporting countries’ needs for testing and assessment of chemicals for endocrine disrupters, while ECHA maintains an endocrine disruptor assessment process and list for substances under assessment.
    This report is a detailed and comprehensive analysis for global Endocrine Disrupting Properties Assessment market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Endocrine Disrupting Properties Assessment market size and forecasts, in consumption value ($ Million), 2021-2032
    Global Endocrine Disrupting Properties Assessment market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
    Global Endocrine Disrupting Properties Assessment market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
    Global Endocrine Disrupting Properties Assessment market shares of main players, in revenue ($ Million), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Endocrine Disrupting Properties Assessment
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Endocrine Disrupting Properties Assessment market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Labcorp, Eurofins Scientific, Intertek, Charles River Laboratories, PerkinElmer, Smithers, Fera Science, Staphyt, TransGenic, ToxStrategies, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market segmentation
    Endocrine Disrupting Properties Assessment market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    In Vitro (Cell-based) Testing
    In Vivo (Animal) Testing
    In Silico (Computational) Modeling
    Others
    Market segment by Endocrine Pathway
    Estrogen Pathway Assessment
    Androgen Pathway Assessment
    Thyroid Pathway Assessment
    Steroid Synthesis Pathway Assessment
    Others
    Market segment by Application
    Environmental Monitoring
    Food Safety
    Cosmetics and Personal Care Products
    Public Health and Disease Prevention
    Others
    Market segment by players, this report covers
    Labcorp
    Eurofins Scientific
    Intertek
    Charles River Laboratories
    PerkinElmer
    Smithers
    Fera Science
    Staphyt
    TransGenic
    ToxStrategies
    LAUS
    Creative Bioarray
    Creative Proteomics
    Compliance Services International
    Xenometrix
    Shenyang SYRICI Testing
    Market segment by regions, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
    South America (Brazil, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe Endocrine Disrupting Properties Assessment product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Endocrine Disrupting Properties Assessment, with revenue, gross margin, and global market share of Endocrine Disrupting Properties Assessment from 2021 to 2026.
    Chapter 3, the Endocrine Disrupting Properties Assessment competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Endocrine Disrupting Properties Assessment market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of Endocrine Disrupting Properties Assessment.
    Chapter 13, to describe Endocrine Disrupting Properties Assessment research findings and conclusion.

    Buy now